Showing 1672 results
-
Press release /Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases. Biosimilar rituximab also recommended to treat blood cancers Comprehensive…
-
Press release /Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar…
-
Press release /Zessly® (infliximab) matched the reference medicine in terms of safety and efficacy at 54 weeks, even in patients who switched from the reference medicine to Zessly[1] Switching from the…
-
Statement /
-
Story /Ice hockey used to help Tyler Patron combat cystic fibrosis, but he hopes the lab could yield stronger medicine.
-
Story /Novartis researchers aim to preserve kidney function – and quality of life – for patients.
-
Featured News /
-
Featured News /
-
Featured News /
Fourteen weeks. That’s how many weeks all new Novartis parents will get as minimum paid parental leave, regardless of gender, rolling out from July 1, 2019.
-
Featured News /
Leprosy is an ancient disease that currently infects more than 200 000 people each year. For more than three decades, Novartis and the Novartis Foundation has been working to reduce the incidence of leprosy, and the Novartis Foundation recently helped establish the Global Partnership for Zero Leprosy in an effort to eliminate the disease.